AstraZeneca’s Phase II Study on AZD0901: A Potential Game-Changer in Cancer Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is conducting a Phase II clinical study titled A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01). The study aims to assess the safety, tolerability, and efficacy of AZD0901, a biologic antibody-drug conjugate, in treating advanced solid tumors expressing Claudin 18.2.

The study is testing AZD0901 both as a standalone treatment and in combination with various chemotherapy agents, including 5-Fluorouracil, Leucovorin, and Gemcitabine, among others. The goal is to determine its effectiveness in treating gastric, pancreatic, and biliary tract cancers.

This open-label, multi-centre study employs a randomized, parallel intervention model without masking, focusing primarily on treatment. It includes several sub-studies targeting different cancer types to evaluate AZD0901’s efficacy as a monotherapy or in combination with other drugs.

The study began on December 13, 2023, with an initial submission date of November 21, 2023. The latest update was submitted on August 1, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.

This clinical update could positively influence AstraZeneca’s stock performance by enhancing investor confidence in the company’s innovative cancer treatments. The study’s outcomes may also impact the competitive landscape, especially if AZD0901 proves effective against these challenging cancers.

The study is ongoing, and further details are available on the ClinicalTrials portal.